🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection

Recruitingn/aAges 18 Years - 80 YearsAllWest China Hospital
NCT07295275 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC). The study aims to compare the outcomes of the trans-arterial ICG staining approach versus the conventional trans-portal (portal vein) ICG staining approach.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-80 years. 2. Postoperative histopathological diagnosis of Hepatocellular Carcinoma (HCC). 3. Underwent ICG fluorescence-guided laparoscopic anatomical liver resection. 4. Child-Pugh Class A or B. 5. ASA score I-III. 6. ECOG Performance Status 0-2. 7. No invasion of major vessels (main portal vein/first-order branches, main hepatic vein). 8. No distant metastasis. Exclusion Criteria: 1. Pathology confirms non-HCC components (e.g., cholangiocarcinoma, combined HCC-ICC) or metastatic liver cancer. 2. Concomitant other active malignancies. 3. Preoperative anti-tumor therapy (TACE, ablation, radiotherapy, systemic therapy) or history of prior hepatectomy. 4. Ruptured tumor. 5. Conversion to open surgery. 6. Unclear surgical records regarding ICG staining method. 7. Intraoperative ICG staining failure (e.g., diffuse staining, unclear boundaries) preventing fluorescence-guided resection. 8. Missing data preventing primary endpoint assessment.
💊

What it tests

  • Laparoscopic Anatomical Liver Resection (guided by transarterial injection of ICG)
📍

Where

3 sites
Beijing Tsinghua Changgung Hospital
Beijing, China
Xuzhou Central Hospital
Xuzhou, China
West China Hospital
Chengdu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy